Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decrease of 14.2% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 179,200 shares, the days-to-cover ratio is currently 6.8 days. Currently, 2.7% of the shares of the company are short sold.
Insider Activity at Aura Biosciences
In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 23,045 shares of company stock worth $177,242 in the last 90 days. 5.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Aura Biosciences
A number of large investors have recently made changes to their positions in AURA. Long Focus Capital Management LLC increased its holdings in shares of Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock valued at $20,861,000 after purchasing an additional 1,404,228 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in shares of Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after purchasing an additional 783,984 shares in the last quarter. B Group Inc. purchased a new position in shares of Aura Biosciences in the 4th quarter valued at about $3,885,000. Franklin Resources Inc. increased its holdings in shares of Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock valued at $15,571,000 after purchasing an additional 215,597 shares in the last quarter. Finally, Ensign Peak Advisors Inc grew its stake in Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company's stock valued at $3,212,000 after acquiring an additional 118,000 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.
Analysts Set New Price Targets
AURA has been the subject of a number of analyst reports. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $23.00.
Check Out Our Latest Analysis on AURA
Aura Biosciences Trading Down 0.3 %
Shares of AURA traded down $0.02 during trading hours on Thursday, reaching $7.63. The company had a trading volume of 128,348 shares, compared to its average volume of 138,717. The firm has a 50 day simple moving average of $8.01 and a 200-day simple moving average of $8.74. The company has a market capitalization of $381.12 million, a price-to-earnings ratio of -4.41 and a beta of 0.29. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38.
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Recommended Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.